Short communicationPublished 5 Jul 2022

Repurposing Inhibitors for SARS-CoV2 Main Protease

Authors: Kumar Sharp

Enzyme Engineering

Volume 11 · Issue 4 · Pages 1–4

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

SARS-CoV2 main protease is important for viral replication and one of the most potential targets for drug development in this current pandemic. Drug repurposing is a promising field to provide potential short-term acceptable therapy for management of coronavirus till a specific anti-viral for coronavirus is developed. In-silico drug repurposing screening is the current fastest way to repurpose drugs by targeting active sites in fraction of seconds. In this study, SARS-CoV2 main protease is being targeted by 1050 FDA-approved drugs to inhibit its activity thereby interfering with viral replication. Chemotherapeutic drugs and anti-retroviral drugs have shown potential binding as inhibitor. In-vitro and clinical trials required to establish final fact.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Longdom does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalEnzyme Engineering
  • SubjectBiochemistry & Biotechnology
  • SubjectEngineering
  • BylineArticles whose byline prints “Kumar Sharp”